Overview:

This educational initiative delivers expert insight across the HER2 expression spectrum, with enduring activities and live, interactive virtual meeting designed to translate evolving evidence into real-world practice. 

Learning Objectives:

• Review updated categories of HER2 expression for breast tumors, with a focus on the categories of HER2 low and HER2 ultralow.
• Apply the latest approaches to interpreting HER2 staining patterns to appropriately communicate expression levels in the pathology report.
• Summarize the latest clinical trial data of antibody-drug conjugates (ADCs) for the treatment of HER2-low and -ultralow, metastatic and/or relapsed/refractory advanced BC.
• Incorporate the latest clinical trial data and guideline recommendations to the optimal treatment selection for patients with metastatic and/or relapsed/refractory advanced BC with HER2-low or -ultralow expression.
• Manage potential adverse events (AEs) that are specific to ADCs used for the treatment of HER2-low and -ultralow BC.

Target Audience:

This initiative has been designed to meet the educational needs of institutional and community-based medical oncology and pathology clinicians with the City of Hope's, Los Angeles Society of Pathologists, Medical Oncology Association of Southern California networks, the surrounding regions, and other clinicians nationwide who are involved in the management of patients with mBC, and national learners.

Register Now!